Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
This observational study of cancer patients diagnosed with Covid-19 (n=890; 218 in the UK) found no evidence that receipt of anti-cancer therapy (chemotherapy, targeted therapy, endocrine therapy and immunotherapy) was associated with mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2020 Category: Consumer Health News Source Type: news

Novel Immune Activator Boosts Immunotherapy Benefit in TNBC Novel Immune Activator Boosts Immunotherapy Benefit in TNBC
The combination of a novel immune activator with pembrolizumab showed good activity, especially in women with disease that converted to triple negative after endocrine therapy.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 30, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

' Eye-Opening': Cognitive Decline With Endocrine Tx for Breast Ca'Eye-Opening': Cognitive Decline With Endocrine Tx for Breast Ca
The loss of cognition that occurs with chemotherapy -- so called chemobrain -- also occurs when women with early breast cancer are treated with endocrine therapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adjuvant Chemoendocrine Therapy May Be Associated With Cognitive Impairment
Results from a subgroup of the TAILORx trial suggested that adjuvant chemoendocrine therapy is associated with significantly greater cancer-related cognitive impairment compared with endocrine therapy alone. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

' Encouraging' Results With Pre-Op Therapy for DCIS'Encouraging' Results With Pre-Op Therapy for DCIS
There's a template now for treating DCIS with pre-operative endocrine therapy, and it shows that 15% of patients have a pathologic complete response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Alopecia Treatment Safe for Breast Cancer Survivors Alopecia Treatment Safe for Breast Cancer Survivors
Spironolactone is safe for the treatment of alopecia in breast cancer survivors taking endocrine therapy, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 26, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

Study Identifies Barriers to Endocrine Therapy Adherence in Breast Cancer Survivors
In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Certain factors linked with discontinuing breast cancer therapy
(Wiley) For women with hormone receptor-positive breast cancer, long-term endocrine therapy can greatly reduce the risk of recurrence. Many women, especially those in underserved populations, do not continue treatment, however. A new Psycho-Oncology study uncovers some of the factors that may be involved. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Oral Vinorelbine With Endocrine Therapy for Breast Cancer Oral Vinorelbine With Endocrine Therapy for Breast Cancer
Is the combination of oral metronomic vinorelbine plus letrozole safe and effective for ER+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Breast Cancer Index and Extended Endocrine Therapy Benefit Breast Cancer Index and Extended Endocrine Therapy Benefit
Might the Breast Cancer Index effectively predict benefit from extended endocrine treatment? Data from the aTTom trial provides insight.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

10-year results of NRG Oncology/NSABP B-42 trial
(NRG Oncology) In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news

Targeted therapy drug helps women with aggressive breast cancer live longer
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - December 11, 2019 Category: Universities & Medical Training Source Type: news

Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Immune checkpoint therapy for ER+ breast cancers, a missed opportunity?
(Baylor College of Medicine) A subset of endocrine therapy-resistant luminal B breast cancers activates immune responses that could be amenable to manipulation with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2019 Category: Cancer & Oncology Source Type: news

Endocrine Therapy Lowers QOL for Breast Cancer Patients
Effects of chemotherapy found to be more transient in comparison (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 25, 2019 Category: Psychiatry Tags: Gynecology, Oncology, Pharmacy, Psychiatry, Journal, Source Type: news

Endocrine Therapy Lowers QOL for Breast Cancer Patients
MONDAY, Nov. 25, 2019 -- Endocrine therapy reduces the quality of life of breast cancer patients, especially for postmenopausal women, according to a study recently published in the Annals of Oncology. Arlindo R. Ferreira, M.D., of the Institut... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2019 Category: Pharmaceuticals Source Type: news

CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer
A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Ask About Sex Life in Breast Cancer Patients on Endocrine Tx Ask About Sex Life in Breast Cancer Patients on Endocrine Tx
A new study shows that almost all postmenopausal women taking endocrine therapy to prevent breast cancer relapses report adverse effects on sexual function.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

High Recurrence Score Linked with Chemotherapy Success in Breast Cancer
The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well. (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Genotyping for breast cancer endocrine therapy cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer
New data for overall survival now establish adding the CDK4/6 inhibitors abemaciclib and ribociclib to endocrine therapy for frontline use in HR+/HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Support for Ovarian Suppression with Endocrine Therapy in Premenopausal Breast Cancer
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Update of this US guidance now includes anastrazole as an option in postmenopausal women at increased risk. Tamoxifen 20 mg/day for 5yrs is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 5, 2019 Category: Consumer Health News Source Type: news

How Does Pharmacy Synchronization Help Endocrine Therapy Adherence?
Could something as simple as synchronizing medicine refills at the pharmacy help improve survival in patients with breast cancer using endocrine therapy? (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can PI3K Inhibitors Reduce Endocrine Therapy Resistance in Early Breast Cancer?
The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole in the neoadjuvant setting. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?
In this article, we provide a case-based expert opinion on the duration of extended adjuvant endocrine therapy, use of biomarkers in guiding this decision, and toxicities to be considered when recommending this treatment. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Shaveta Vinayak, MD, MS, Nancy E. Davidson, MD Source Type: news

Endocrine Therapy Nonadherence and Discontinuation in Women Endocrine Therapy Nonadherence and Discontinuation in Women
What factors contribute to higher nonadherence rates reported in black women with hormone positive breast cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Premenopausal Women With Breast Cancer; New TAILORx Data Premenopausal Women With Breast Cancer; New TAILORx Data
An analysis of TAILORx showed that adding clinical risk refines its genomic risk model and may now identify a group of premenopausal women who may benefit from chemotherapy added to endocrine therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Palbociclib and Endocrine Therapy for Advanced Breast Cancer Palbociclib and Endocrine Therapy for Advanced Breast Cancer
An analysis of longer-term PALOMA safety data finds that palbociclib plus endocrine therapy is not associated with specific cumulative or delayed toxicities.Journal of the National Cancer Institute (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 7, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news

ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
TUESDAY, June 4, 2019 -- For premenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer, adding ribociclib to standard-of-care endocrine therapy is associated with improved overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1]. (Source: World Pharma News)
Source: World Pharma News - June 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer
Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 2, 2019 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.The study involved 672 women aged 25 to 59 when the study began who had advanced hormone-receptor positive/HER2- breast cancer. Seventy percent of the women who took the combination therapy wer...
Source: UCLA Newsroom: Health Sciences - June 1, 2019 Category: Universities & Medical Training Source Type: news

Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer
The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer
May 24, 2019 -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2019 Category: Drugs & Pharmacology Source Type: news

Cognitive-Behavioral Therapy Reduces Endocrine Tx Side Effects Cognitive-Behavioral Therapy Reduces Endocrine Tx Side Effects
Cognitive-behavioral therapy may offer breast cancer patients an option to manage the side effects of adjuvant endocrine therapy, according to a new study.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Ibrance Approval Expanded to Include Men With Breast Cancer
Kinase inhibitor approved in combination with endocrine therapy for male patients with breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 5, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA expands approved use of metastatic breast cancer treatment to include male patients
The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 4, 2019 Category: American Health Source Type: news

FDA expands approved use of metastatic breast cancer treatment to include male patients
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: World Pharma News)
Source: World Pharma News - April 4, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Surgery Tied To 44% Increased Survival In Women With Advanced Breast Cancer
(CNN) — Surgery is tied to improved chances of survival among stage 4 breast cancer patients, a new study suggests, but who has access to surgery and who doesn’t can vary drastically, based on factors including income level and where treatment is administered. Surgery to remove tumors was associated with a 44% increased chance of survival within an average followup period of 21 months, according to the abstract, to be presented at the American Association for Cancer Research’s annual meeting in Atlanta this week. “If breast surgery is to be considered by patients and providers when deciding treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer CNN Source Type: news

FFNP-PET could aid breast cancer treatment evaluation
PET imaging with fluoro furanyl norprogesterone (FFNP) could provide a new...Read more on AuntMinnie.comRelated Reading: JNM: Imaging agents predict endocrine therapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 12, 2019 Category: Radiology Source Type: news

Endocrine Tx Does Not Impair Neuropsychological Performance
WEDNESDAY, Dec. 19, 2018 -- For early-stage breast cancer survivors, endocrine therapy (ET) appears to have no effect on neuropsychological performance or impairment over six years of follow-up, according to a study published online Nov. 28 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 19, 2018 Category: Pharmaceuticals Source Type: news

Surgery or Endocrine Therapy for Breast CA in Older Women? Surgery or Endocrine Therapy for Breast CA in Older Women?
Dr Lowenfels challenges the findings of a recent study that suggests surgery as the better option in treating older women with early-stage breast cancer.Medscape General Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2018 Category: Consumer Health News Tags: General Surgery Viewpoint Source Type: news

UCLA research suggests widely used breast cancer therapy doesn ’t cause cognitive decline
UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.Endocrine therapy has become an essential part of treatment for the many women diagnosed with hormone-receptor positive breast cancer, in which hormones, such as estrogen, promote cancer growth. The endocrine treatment helps lower the recurrence and reduce the risk of death from breast cancer by interfering with how a woman ’s own hormones can continue to support the growth of dormant cancer cells. Yet, there has been limited evidence ...
Source: UCLA Newsroom: Health Sciences - November 28, 2018 Category: Universities & Medical Training Source Type: news

Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Black women more likely to skip crucial breast cancer treatments
(Oxford University Press USA) A new study in the Journal of the National Cancer Institute finds that black women are more likely to skip hormone therapy treatments, also known as endocrine therapy, for breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2018 Category: Cancer & Oncology Source Type: news

MONALEESA-3 Expands Endocrine Tx for Advanced Breast Cancer MONALEESA-3 Expands Endocrine Tx for Advanced Breast Cancer
The MONALEESA-3 trial marks an important step forward for endocrine therapies for advanced breast cancer, argues Lidia Schapira.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Obese Breast Cancer Patients and Survivors: Management Considerations
This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Jennifer Y. Sheng, MD, Dipali Sharma, MS, PhD, Gerald Jerome, PhD, Cesar Augusto Santa-Maria, MD Source Type: news